Corrigan-Curay leaving FDA as acting head of CDER

Jacqueline Corrigan-Curay informed FDA staff Monday that she will retire in July. Corrigan-Curay has served as acting director of the Center for Drug Evaluation and Research since January, when Patrizia Cavazzoni stepped down from the position. In her nine-year career at CDER, Corrigan-Curay has served as principal deputy director and director of the Office of Medical Policy. Her departure follows the firings and resignations of many senior FDA staff over the past five months.

Last week, Nicole Verdun, director of the Office of Therapeutic Products at the Center for Biologics (CBER) was abruptly placed on administrative leave. Other officials who have left the agency since the beginning of the year include CBER Director Peter Marks; FDA Chief Medical Officer Hilary Marston; Associate Commissioner for Inspections and Investigations Michael Rogers; CDER Office of New Drugs Director Peter Stein; and Deputy Director for Regulatory Programs Douglas Throckmorton. In December, Principal Deputy Commissioner Namandjé Bumpus left the agency, while Robert “Bob” Temple, senior adviser for clinical science at CDER, announced his retirement...